InflaRx N.V. (IFRX) Income Statement
IFRX 2025 at a glance
Fiscal year ended December 31, 2025 · eurosIFRX revenue and net income
Where IFRX's revenue goes
2025Each bar shows an amount and its share of revenue. IFRX kept −155,582.1% of revenue as net income.
IFRX profit margins
IFRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −82.3% | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IFRX income statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €29,331 | €165,789 | €63,089 | €0 | €0 | €0 | €0 | €0 | €231,000 | €0 |
| Cost of revenue | €7.3M | €3.3M | €532,262 | €627,008 | €791,258 | €812,474 | €742,247 | €179,570 | €66,691 | €35,658 |
| Gross profit | −€7.2M | −€3.2M | −€469,173 | −€627,008 | −€791,258 | −€812,474 | −€742,247 | −€179,570 | −€68,420 | −€35,658 |
| Research & development | €25.7M | €35.4M | €41.0M | €37.5M | €35.7M | €25.7M | €44.6M | €25.0M | €14.4M | €5.3M |
| Sales, general & admin | €15.5M | €15.3M | €14.2M | €14.3M | €11.4M | €7.9M | €12.5M | €12.8M | €5.1M | €1.8M |
| Total operating expenses | €41.0M | €49.8M | €44.1M | €32.2M | €47.6M | €33.9M | €56.8M | €37.5M | €18.8M | €6.9M |
| Operating income | −€48.3M | −€52.9M | −€44.6M | −€32.2M | −€47.6M | −€33.9M | −€56.8M | −€37.5M | −€19.4M | −€6.9M |
| Interest income | €1.8M | €3.2M | €3.0M | €608,679 | €109,391 | €887,702 | €2.8M | €2.2M | €130,000 | €1,000 |
| Interest expense | €37,690 | €20,655 | €35,628 | €45,250 | €24,769 | €26,000 | €22,200 | €0 | €2.2M | €1.8M |
| Income before taxes | −€45.6M | −€46.1M | −€42.7M | −€29.5M | −€45.6M | −€34.0M | −€53.3M | −€29.8M | −€24.2M | −€8.9M |
| Income taxes | €12,282 | €5,217 | −€1 | −€2.4M | €24,768 | €26,000 | −€3.5M | €7.7M | €2.2M | €1.8M |
| Net income | −€45.6M | −€46.1M | −€42.7M | −€29.5M | −€45.6M | −€34.0M | −€53.3M | −€29.8M | −€24.2M | −€8.9M |
| EBITDA | −€45.2M | −€45.6M | −€42.1M | −€28.8M | −€44.9M | −€33.2M | −€56.1M | −€37.3M | −€21.9M | −€7.1M |
| Gross margin | −24,677.9% | −1,900.8% | −743.7% | — | — | — | — | — | −29.6% | — |
| Operating margin | −164,525.5% | −31,911.4% | −70,685.6% | — | — | — | — | — | −8,417.7% | — |
| Net margin | −155,582.1% | −27,785.0% | −67,630.7% | — | — | — | — | — | −10,492.6% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €23,830 | €39,432 | €0 | €2,286 | €60,803 | €0 | €0 | €0 | €0 |
| Cost of revenue | €0 | €88,615 | €4.9M | €333 | €2.4M | €2.8M | €277,146 | €255,116 | €145,039 | €146,485 | €151,247 | €151,469 |
| Gross profit | €0 | −€88,615 | −€4.9M | €23,497 | −€2.4M | −€2.8M | −€274,860 | −€194,313 | −€145,039 | −€146,485 | −€151,247 | −€151,469 |
| Research & development | €4.7M | €4.2M | €5.3M | €6.2M | €7.2M | €6.9M | €8.1M | €7.3M | €10.9M | €14.7M | €8.3M | €7.5M |
| Sales, general & admin | €2.5M | €3.2M | €4.6M | €2.6M | €3.7M | €5.7M | €4.2M | €2.9M | €3.5M | €3.6M | €2.5M | €3.1M |
| Total operating expenses | €7.1M | €7.2M | €8.0M | €9.5M | €10.5M | €6.9M | €13.0M | €11.0M | €9.9M | €10.6M | €7.7M | €8.6M |
| Operating income | −€7.1M | −€7.2M | −€12.9M | −€9.5M | −€12.8M | −€9.8M | −€13.3M | −€11.2M | −€9.9M | −€10.6M | −€7.7M | −€8.6M |
| Interest income | €770,661 | €334,768 | €391,309 | €438,134 | €522,221 | €674,338 | €1.1M | €1.2M | €1.1M | €456,036 | €298,558 | €199,758 |
| Interest expense | €14,643 | €15,052 | €15,890 | €14,359 | €3,355 | €4,779 | €21,671 | €5,327 | €5,498 | €5,931 | €5,992 | €6,891 |
| Income before taxes | −€10.6M | −€5.6M | −€10.6M | −€12.2M | −€14.3M | −€5.1M | −€15.9M | −€7.5M | −€8.2M | −€11.1M | −€8.0M | −€7.9M |
| Income taxes | — | — | −€24,079 | €12,282 | — | — | −€2 | €4,897 | €5,053 | €1.1M | €731,586 | −€882,369 |
| Net income | −€10.6M | −€5.6M | −€10.6M | −€12.3M | −€14.4M | −€5.1M | −€15.9M | −€7.5M | −€8.2M | −€11.1M | −€8.0M | −€7.9M |
| EBITDA | −€10.5M | −€5.5M | −€10.5M | −€12.1M | −€14.2M | −€5.0M | −€15.8M | −€7.3M | −€8.1M | −€10.9M | −€7.9M | −€7.8M |
| Gross margin | — | — | — | 98.6% | −5,985.4% | — | −12,023.6% | −319.6% | — | — | — | — |
| Operating margin | — | — | — | −39,769.2% | −32,524.7% | — | −582,075.0% | −18,339.3% | — | — | — | — |
| Net margin | — | — | — | −51,452.3% | −36,559.8% | — | −696,857.2% | −12,255.0% | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in IFRX's financial statements (latest annual report filed March 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IFRX financial results
In fiscal year 2025 (ended December 31, 2025), InflaRx reported revenue of €0.0 million, down 82.3% from the year before. It had a net loss of €45.6 million, a net profit margin of −155,582.1%. Figures are in euros, the currency of its financial statements.
See the IFRX stock overview for the latest quote and news, or the IFRX chart for price history and technical indicators.
IFRX income statement FAQ
What is InflaRx's annual revenue?
InflaRx reported total revenue of €0.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 82.3% from €0.2 million the previous year.
Is InflaRx profitable?
No. InflaRx reported a net loss of €45.6 million in fiscal 2025, a net profit margin of −155,582.1%; its operating margin was −164,525.5%.
What is InflaRx's gross margin?
InflaRx's gross margin was −24,677.9% in fiscal 2025: for every $100 of revenue, InflaRx kept $-24678 after the direct cost of its products and services.
How much does InflaRx spend on research and development?
InflaRx spent €25.7 million on research and development in fiscal 2025, 87,691.5% of revenue.
When will InflaRx report its next earnings?
InflaRx is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens.
When does InflaRx's fiscal year end?
InflaRx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 20, 2026.